Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Following the bank holiday weekend, Richmond MayFest trustees reported a bustling and enjoyable three days of music, dance, ...

A woman was killed and a child was injured in a crash in Marshall County on Friday.

Chevron, Exxon Mobil and TotalEnergies are among other big oil companies that could be considering a deal for BP, a report ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Hook: Big Oil Meets Hydrogen Reality Check Exxon Mobil just made a bold move. They’ve inked a binding agreement with Japan’s Marubeni to ship out 250,000 m ...

An elegant screening strategy unveils a molecular actor that connects widespread changes in mRNA processing with a nutrient-sensing protein modification.

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.

Exxon Mobil signed a long-term agreement to supply low-carbon ammonia to Japan's Marubeni, in the first signed customer ...